Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation

PL Weiden, KM Sullivan, N Flournoy… - … England Journal of …, 1981 - Mass Medical Soc
PL Weiden, KM Sullivan, N Flournoy, R Storb, ED Thomas, Seattle Marrow Transplant Team
New England Journal of Medicine, 1981Mass Medical Soc
ALLOGENEIC marrow transplantation is being used with increasing frequency in the
treatment of acute leukemia. 1 2 3 4 Recurrent leukemia is an uncommon cause of
therapeutic failure in patients with acute nonlymphoblastic leukemia who receive transplants
while the disease is in first remission, 1, 3, 4 but recurrence is a major cause of failure in
patients with acute nonlymphoblastic leukemia or acute lymphoblastic leukemia who receive
transplants with the disease in relapse or in a second or subsequent remission. 2, 3, 5 …
ALLOGENEIC marrow transplantation is being used with increasing frequency in the treatment of acute leukemia.1 2 3 4 Recurrent leukemia is an uncommon cause of therapeutic failure in patients with acute nonlymphoblastic leukemia who receive transplants while the disease is in first remission,1 , 3 , 4 but recurrence is a major cause of failure in patients with acute nonlymphoblastic leukemia or acute lymphoblastic leukemia who receive transplants with the disease in relapse or in a second or subsequent remission. 2 , 3 , 5 Attempts to decrease the rate of leukemic relapse with more vigorous chemoradiotherapy conditioning regimens have generally been unsuccessful.2 , 6 , 7 However, we previously reported that the rate of leukemic . . .
The New England Journal Of Medicine